AbbVie finds a PEARL of great price with ABT-450 combo in hepatitis C
This article was originally published in Scrip
Executive Summary
The first Phase III data for AbbVie's ABT-450-based combination therapy for hepatitis C have been presented showing sustained viral response rates at 12 weeks of up to 99.5%.